エピソード

  • S1 Ep169: Best Practices for the Medical Oncology Boards

    S1 Ep169: Best Practices for the Medical Oncology Boards
    2025/07/07
    The medical oncology board examinations are a pivotal time in a clinician's career. However, preparing for and taking this exam comes as a crucial moment when residents/fellows begin their transition to attending.

    While in theory, the process of taking an exam and then beginning a new job sounds simple, it is quite complex. The hematology/oncology boards require rigorous preparation. The exam is followed by the new attending position, where clinicians, for the first time, are on their own, making treatment decisions and leading a team.

    ONCOLOGY® spoke with leading clinicians as well as those who are just beginning their careers about this time, and how they handled studying while experiencing personal and professional changes.

    Eric K. Singhi, MD, assistant professor in the Department of General Oncology, Division of Cancer Medicine, and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, focused on:

    · His transition from fellow to attending (0:58)

    · Where students should focus their efforts on studying (2:11)

    · Advice he would give to those currently studying (2:47)

    Nicholas James Hornstein, MD, PhD, assistant professor at Northwell Health Cancer Institute, discussed:

    · Studying for the boards while balancing a new career (3:18)

    · Specific study areas the exam focuses on (5:43)

    Marc J. Braunstein, MD, associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine, fellowship program director in hematology/oncology at NYU Langone Health - Long Island, and codirector of the Hematology-Oncology System at NYU Grossman Long Island School of Medicine, highlighted:

    · How to prepare fellows for the career transition (7:11)

    · Advice he gives about this transition (8:17)

    Nerea M. Lopetegui-Lia, MD, assistant professor in the College of Medicine at The Ohio State University Comprehensive Cancer Center-The James, spoke about:

    · Best review practices for the exam (9:01)

    · Advice she would give to those studying (10:15)

    MinhTri Nguyen, MD, a medical oncologist with Stanford Medicine, focused on:

    · As a leadership coach, helping prepare residents/fellows for the career transition (11:36)

    · Advice he would give to those studying (14:34)
    続きを読む 一部表示
    17 分
  • S1 Ep168: Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

    S1 Ep168: Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis
    2025/06/30
    In a conversation with CancerNetwork®, Benjamin Golas, MD, spoke about the current treatment landscape for patients with peritoneal carcinomatosis, discussing how the use of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) may offer improvements in clinical outcomes.

    Golas is the chief of Surgical Oncology of the Central Region for Hackensack Meridian Health.

    According to Golas, standard therapeutic approaches include combining cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), which may cause collateral damage to healthy tissue while eliciting toxicities such as nausea, vomiting, and bone marrow suppression. Additionally, certain surgical procedures may last up to 14 hours and confer an extensive morbidity profile, thereby increasing complication rates.

    Golas described how PIPAC, a minimally invasive laparoscopic technique, may help avoid pain and other adverse effects associated with surgery while facilitating more direct delivery of chemotherapy in the peritoneal cavity. He noted that treatment with PIPAC typically takes 45 minutes to an hour, allowing some patients to return home on the same day of the procedure.

    Although clinicians are still learning the correct indications for PIPAC, Golas stated that any patient with peritoneal carcinomatosis should be a candidate to receive treatment with this strategy. Furthermore, he described how the next steps for improving outcomes in this population include finding new ways to incorporate PIPAC into more extensive treatment plans for patients.

    “PIPAC is a new treatment and a new potential option that doesn't replace systemic chemotherapy, but I do think it can work in conjunction with systemic chemotherapy. We can offer this bimodal approach where we're directly treating the peritoneal disease and offering [intravenous] chemotherapy,” Golas stated. “We clearly have a long way to go in terms of clinical trials and learning what the best ways are to use this. But there are patients out there who will benefit from that, so I think referral to a center that focuses and has expertise in PIPAC for patients with peritoneal carcinomatosis is critical.”
    続きを読む 一部表示
    16 分
  • S1 Ep167: Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting

    S1 Ep167: Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting
    2025/06/23
    In the wake of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® put together an X Spaces discussion hosted by Stephen Liu, MD, and Joshua Sabari, MD, to highlight the most intriguing and practice-changing lung cancer abstracts. Discussed topics ranged from long-term follow-up with commonplace therapies to an analysis of what time of day is the best to administer immunochemotherapy.

    Liu, an associate professor of Medicine at Georgetown University, and the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Sabari, an assistant professor in the Department of Medicine at the NYU Grossman School of Medicine, and the director of High Reliability Organization Initiatives at the Perlmutter Cancer Center, shared expert insights on the latest non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) breakthroughs.

    Trials of note that they discussed included:

    The phase 3 DeLLphi-304 trial (NCT05740566) - Tarlatamab (Imdelltra) versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304.1

    The phase 3 IMforte trial (NCT05091567) - Lurbinectedin (Zepzelca; lurbi) + atezolizumab (Tecentriq; atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial.2

    The phase 3 CheckMate 816 trial (NCT02998528) - Overall survival with neoadjuvant nivolumab (Opdivo; NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.3

    The phase 3 PACIFIC15 trial (NCT05549037) - Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non–small cell lung cancer.4

    The phase 3 Beamion LUNG-1 trial (NCT04886804) - Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non–small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial.5

    The phase 3 ARTEMIA trial (NCT06472245) - Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non–small cell lung cancer and secondary resistance to immunotherapy.

    References

    1. Rudin C, Mountzios G, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304. J Clin Oncol. 2025;43(suppl 17):LBA8008. doi:10.1200/JCO.2025.43.17_suppl.LBA8008
    2. Paz-Ares L, Borghaei H, Liu SV, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial. J Clin Oncol. 2025;43(suppl 16):8006. doi:10.1200/JCO.2025.43.16_suppl.8006
    3. Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab + chemotherapy in patients with resectable NSCLC in CheckMate 816. J Clin Oncol. 2025;43(suppl 17):LBA8000. doi:10.1200/JCO.2025.43.17_suppl.LBA8000
    4. Zhang Y, Huang Z, Zeng L, et al. Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. J Clin Oncol. 2025;43(suppl 16):8516. doi:10.1200/JCO.2025.43.16_suppl.8516
    5. Sabari JK, Nadal E, Hendriks L, et al. Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial. J Clin Oncol. 2025;43(suppl 16):8620. doi:10.1200/JCO.2025.43.16_suppl.8620
    6. Liu SV, Guibert C, Tostivint EP, et al. Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy. J Clin Oncol. 2025;43(suppl 16):TPS8651. doi:10.1200/JCO.2025.43.16_suppl.TPS8651
    続きを読む 一部表示
    45 分
  • S1 Ep166: Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

    S1 Ep166: Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC
    2025/06/16
    In the third edition of a special podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about optimal strategies for incorporating different therapeutic agents into lung cancer care. As part of the latest discussion, the group highlighted the relevant efficacy data, administration protocols, and toxicity management considerations associated with TROP2-directed antibody-drug conjugates (ADCs) in patients with non–small cell lung cancer (NSCLC).

    Morgensztern is a professor of Medicine and the clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital.

    Morgensztern opened the discussion by highlighting the characteristics of prominent TROP2-targeting ADCs in NSCLC management, which included sacituzumab govitecan-hziy (Trodelvy), datopotamab deruxtecan-dlnk (Datroway), and sacituzumab tirumotecan (sac-TMT). Additionally, he reviewed data from clinical trials assessing these ADCs across different NSCLC populations, including the phase 3 EVOKE-01 trial (NCT05089734) showing a numerical overall survival (OS) improvement with sacituzumab govitecan vs docetaxel.

    Regarding the safety profiles of these ADCs, Flanagan described the unique toxicities associated with the agents’ payloads as well as potential off-target effects. On top of myelosuppression, fatigue, and diarrhea, she stated that these therapies may cause more visceral organ toxicities like keratitis of the eye and interstitial lung disease. According to Flanagan, some prophylactic measures in the event of certain toxicities include frequent salt and baking soda mouth rinses as well as oral dexamethasone.

    Mann then outlined the dosing variability considerations and supportive care measures surrounding the use of agents like sacituzumab govitecan. She emphasized continuously re-educating patients about expected toxicities and supportive care strategies as they undergo these infusion-based therapies to help avoid surprise instances of ocular toxicity, diarrhea, and other adverse effects.

    Reference

    Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42(24):2860-2872. doi:10.1200/JCO.24.00733
    続きを読む 一部表示
    24 分
  • S1 Ep165: CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

    S1 Ep165: CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025
    2025/06/09
    CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.

    Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University Health Stephenson Cancer Center and serves as an ambassador for ASCO.

    The group highlighted several late-breaking abstracts, plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:

    · Phase 1b/2 CARTITUDE-1 trial (NCT03548207, NCT05201781)

    o Long-term follow-up showed that approximately one-third (33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti).

    o An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.

    o With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-not evaluable [NE]).

    · Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use

    o Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.

    o Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.

    o Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.

    · Phase 1b/2 NEXICART-2 trial (NCT06097832)

    o Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.

    o Among 12 patients who received the agent at 450 x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively.

    o With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.


    References

    1. Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.7507

    2. Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.7023

    3. Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508. doi:10.1200/JCO.2025.43.16_suppl.7508
    続きを読む 一部表示
    35 分
  • S1 Ep164: Exploring Burnout Causes and Management in Oncologic Practice

    S1 Ep164: Exploring Burnout Causes and Management in Oncologic Practice
    2025/06/02
    In this episode, CancerNetwork® spoke with Eric Winer, MD, director of the Yale Cancer Center; president and physician-in-chief at Smilow Cancer Hospital; deputy dean for cancer research, Alfred Gilman Professor of Pharmacology, and Professor of Medicine at Yale School of Medicine; and chair of the association board for the American Society of Clinical Oncology (ASCO), about the current state of oncologist burnout, steps that can be taken to ameliorate it, and how it currently impacts professionals in the field.

    Causes of workplace burnout that authors identified in a paper published in the Journal of Clinical Oncology in January 2025 included the use of electronic health records, staffing levels, payer authorizations, hours worked, and age. Additionally, published results from the survey revealed a 14% increase in the rate of oncologists who experienced workplace burnout from 2013 to 2023 (P <.01). Moreover, a significant correlation between being a caregiver for someone at home and workplace burnout was observed.

    Winer began by defining workplace burnout, emphasizing that it is not exclusive to oncology, and that many oncologists resist burnout by focusing on the mission-driven nature of the work. Then, he speculated how oncologist burnout may have increased from 2013 to 2023, suggesting that it may have been related to a larger societal trend due to increased awareness of it. Furthermore, he suggested that the COVID-19 pandemic may have exacerbated fatigue, as well as the growing utilization of telehealth and documentation, which take oncologists away from personal engagement with patients.

    He then explored how the workforce might be impacted by burnout, highlighting a sizeable percentage of oncologists who claim to be nearing retirement age. Based on this trend, there may be a need for workforce expansion, as well as the need to embrace a more multidisciplinary approach to help oncologists deliver patient care. Winer concluded by outlining how he mitigates burnout personally, as well as his thoughts regarding how oncology has progressed since his career began.

    Reference

    Schenkel C, Levit LA, Kirkwood K, et al. State of professional well-being, satisfaction, and career plans among US oncologists in 2023. J Clin Oncol. Published online January 29, 2025. doi:10.1200/OA.24.00010
    続きを読む 一部表示
    20 分
  • S1 Ep163: Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

    S1 Ep163: Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025
    2025/05/26
    Ahead of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with a variety of oncology experts about the late-breaking abstracts, plenary sessions, and other key presentations that may shift the paradigm across different cancer care fields. They highlighted anticipated clinical trial results that may transform the standard of care for gynecologic malignancies, lung cancer, and other disease types.

    Rachel N. Grisham, MD, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at MSK Westchester of Memorial Sloan Kettering Cancer Center, shared her anticipation of findings from the phase 3 ROSELLA trial (NCT05257408) assessing relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. She stated she was excited to see if the data may represent a new opportunity for this patient population.

    Next, MinhTri Nguyen, MD, a medical oncologist and hematologist at Stanford Health Care, highlighted a few breast cancer presentations to look out for. These topics included a plenary session on data from the phase 3 SERENA-6 study (NCT04964934) evaluating camizestrant in combination with CDK4/6 inhibitors for those with hormone receptor–positive, HER2-negative advanced breast cancer harboring emergent ESR1 mutations.

    Additionally, Eric K. Singhi, MD, assistant professor in the Department of General Oncology in the Division of Cancer Medicine, and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, spoke about a range of potentially practice-changing results in the lung cancer field. For example, he described a session focused on primary results of the phase 3 IMforte trial (NCT05091567) assessing lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) for those with extensive-stage small cell lung cancer (ES-SCLC). According to Singhi, data from IMforte may shift the paradigm of maintenance therapy for this SCLC population.

    In the world of head and neck cancer, Douglas R. Adkins, MD, associate professor of Internal Medicine, Division of Oncology, Section of Medical Oncology at Washington University School of Medicine in St. Louis, Missouri, highlighted the session on the phase 3 NIVOPOSTOP GORTEC 2018-01 trial (NCT03576417). Investigators of this study evaluated nivolumab (Opdivo) in combination with chemoradiotherapy for those with resected head and neck squamous cell carcinoma. Adkins noted his excitement to see how these data may impact the standard of care, particularly for patients in Europe, where investigators conducted the study.

    As part of an Oncology Decoded discussion, Benjamin Garmezy, MD, the associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, discussed key abstracts in bladder cancer. One specific presentation included additional findings from the phase 3 NIAGARA trial (NCT03732677), which may show how circulating tumor DNA can influence treatment decision-making regarding perioperative durvalumab (Imfinzi) for patients with muscle-invasive bladder cancer.
    続きを読む 一部表示
    11 分
  • S1 Ep162: Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

    S1 Ep162: Leveraging Artificial Intelligence to Bolster Equitable Cancer Care
    2025/05/19
    In a conversation with CancerNetwork®, Viviana Cortiana, MS4, and Yan Leyfman, MD, spoke about their manuscript titled “Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity,” which they published in the April 2025 issue of ONCOLOGY®.

    Cortiana is a medical student in the Department of Medical and Surgical Sciences at the University of Bologna. Leyfman is a resident physician from the Icahn School of Medicine of the Mount Sinai Health System.

    Cortiana highlighted how artificial intelligence (AI)–based tools may mitigate the overdiagnosis of cancers, although she noted a need to validate these devices with diverse and high-quality datasets to avoid the risk of biased models. Additionally, she described how developing population-specific AI models may improve predictive accuracy in diagnosis as well as treatment planning, which can especially benefit patients in low- and middle-income countries.

    As part of ethically applying the use of AI to oncology and delivering equitable cancer care, Leyfman emphasized core pillars such as data security, transparency, clinical validation, and combatting algorithmic bias. Furthermore, he stated that potential applications of these tools include mobile diagnostics, cloud-based platforms, and remote consultation, which can help increase access to care. Regarding the potential next steps in the field, he highlighted that global partnerships with parties such as tech companies, governments, and non-governmental organizations may assist with the funding and deployment of AI tools, especially for underserved regions.

    “The future of AI in oncology is increasingly promising, not just in pushing the boundaries of what's possible in cancer care but also making sure that more precise and more accessible worldwide therapies are available,” Leyfman stated. “AI has the potential to fundamentally change how we detect, treat, and monitor [cancer], but realizing that promise, especially in a way that's equitable, will require collaboration, validation, thoughtful implementation, and a commitment to leaving no patient behind.”
    続きを読む 一部表示
    15 分